{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:16:49Z","timestamp":1792441009633,"version":"4.5.0"},"reference-count":79,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2015,8,3]]},"DOI":"10.1517\/13543784.2015.1059820","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T06:59:20Z","timestamp":1436425160000},"page":"1111-1121","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Beclabuvir for the treatment of hepatitis C"],"prefix":"10.1517","volume":"24","author":[{"given":"Ivan","family":"Gentile","sequence":"first","affiliation":[{"name":"University of Naples \u2018Federico II,\u2019 Department of Clinical Medicine and Surgery","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[{"name":"University of Naples \u2018Federico II,\u2019 Department of Clinical Medicine and Surgery","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[{"name":"University of Naples \u2018Federico II,\u2019 Department of Clinical Medicine and Surgery","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Enrico","family":"Maraolo","sequence":"additional","affiliation":[{"name":"University of Naples \u2018Federico II,\u2019 Department of Clinical Medicine and Surgery","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Borgia","sequence":"additional","affiliation":[{"name":"University of Naples \u2018Federico II,\u2019 Department of Clinical Medicine and Surgery","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,7,9]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12371"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.8352"},{"key":"e_1_3_2_6_1","first-page":"00466","article-title":"Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C","volume":"13","author":"Sagnelli E","year":"2013","unstructured":"Sagnelli E, Pisaturo M, Stanzione M, et al. Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;13:00466-7","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_2_7_1","first-page":"00687","article-title":"Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C","volume":"21","author":"Coppola N","year":"2013","unstructured":"Coppola N, Zampino R, Bellini G, et al. Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol 2013;21:00687-3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_2_8_1","first-page":"773","article-title":"Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection","volume":"27","author":"Gentile I","year":"2013","unstructured":"Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7","journal-title":"In Vivo"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.09.009"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30900-7"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318157464b"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.9.1696"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1665-2681(19)30803-8","article-title":"Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration","volume":"14","author":"Zampino R","year":"2015","unstructured":"Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol 2015;14:75-82","journal-title":"Ann Hepatol"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i18.2793"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.023"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0748-8"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060325b"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.12.003"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152606776056706"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903501505"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986709787581789"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.04.005"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990178"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.892581"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887108666131213120354"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887109666140529222602"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867321666140706125950"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S66731"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.940898"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.945432"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.902049"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.921680"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.982274"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2014-110051"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.929497"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)70127-1","article-title":"A pill a day keeps HCV away","author":"Gentile BG","year":"2015","unstructured":"Gentile BG. A pill a day keeps HCV away. Lancet Infect Dis 2015; In press","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.6.3753-3760.1994"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000032"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2009.05.001"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770802672598"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13034"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02699.x"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2102169"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986711798347234"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867321666131228222215"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12028"},{"key":"e_1_3_2_52_1","first-page":"105","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"Gallay PA","year":"2013","unstructured":"Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des 2013;7:105-15","journal-title":"Drug Des"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4016894"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02495-13"},{"key":"e_1_3_2_55_1","first-page":"311","article-title":"NS5B polymerase non-nucleoside inhibitors","author":"Fenaux M","year":"2011","unstructured":"Fenaux M, Mo H. NS5B polymerase non-nucleoside inhibitors. Hepatitis C 2011;311-20","journal-title":"Hepatitis C"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506407200"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.24.13225-13231.2003"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.613653"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm201384j"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505423200"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-12"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02239-12"},{"key":"e_1_3_2_63_1","article-title":"In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir","author":"Friborg J","year":"2014","unstructured":"Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther 2014. [Epub ahead of print]","journal-title":"Infect Dis Ther"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02579-13"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"e_1_3_2_66_1","first-page":"S63","article-title":"Evaluation of pharmacokinetic Drug\u2013Drug Interaction (DDI) between BMS-791325, an NS5B non-nucleotide polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1-infected patients Poster 451","volume":"58","author":"Wang X","year":"2013","unstructured":"Wang X, Li W, Huang SP, et al. Evaluation of pharmacokinetic Drug\u2013Drug Interaction (DDI) between BMS-791325, an NS5B non-nucleotide polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1-infected patients Poster 451. J Hepatol 58 2013;58:S63-227","journal-title":"J Hepatol 58"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.8.1065"},{"key":"e_1_3_2_68_1","volume-title":"The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir\/asunaprevir\/beclabuvir. P0790 P","author":"Adamczyk R","year":"2015","unstructured":"Adamczyk R, Sims K, Hesney M, et al. The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir\/asunaprevir\/beclabuvir. P0790 P. EASL-50th International Liver Congress; Vienna: 2015"},{"key":"e_1_3_2_69_1","unstructured":"Everson GT Thuluvath PJ Lawitz E et al. All-oral combination of daclatasvir asunaprevir and BMS-791325 for HCV genotype 1 infection Oral 25. Conference on retroviruses and opportunistic infections (CROI); 3 \u2013 6 March 2014; Boston MA"},{"key":"e_1_3_2_70_1","unstructured":"Everson G Sims KD Thuluvath PJ et al. Daclatasvir in combination with asunaprevir and beclabuvir for prior null responders with chronic HCV genotype 1 infection Poster 1943. Poster presented at The liver meeting\u00ae 2014 the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 7 \u2013 11 November 2014; Boston MA"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.025"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"e_1_3_2_73_1","unstructured":"Muir A Poordad F Lalezari J et al. All-oral fixed-dose combination therapy with daclatasvir\/asunaprevir\/beclabuvir \u00b1 ribavirin for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results. Oral presentation Oral LB-2. The Liver Meeting\u00ae 2014 the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 7-11 November 2014; Boston MA"},{"key":"e_1_3_2_74_1","article-title":"A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1","author":"Tatum H","year":"2014","unstructured":"Tatum H, Thuluvath PJ, Lawitz E, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1. J Viral Hepat 2014. [Epub ahead of print]","journal-title":"J Viral Hepat"},{"key":"e_1_3_2_75_1","doi-asserted-by":"crossref","unstructured":"Tatum H Thuluvath P Lawitz E et al. Safety and efficacy of BMS-791325 a non-nucleoside NS5B polymerase inhibitor combined with peginterferon alfa-2a and ribavirin in treatment-naive patients infected with hepatitis c virus genotype 1 Poster 1126. Journal of Hepathology. The 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1\u20135 November Washington DC; 2013. p. S182","DOI":"10.1016\/S0168-8278(12)61175-1"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03851-14"},{"key":"e_1_3_2_77_1","volume-title":"Long-term follow-up analysis of RAVS in HCV NS3, NS5A, and NS5B in DAA therapy failure patients. Abstract P0767","author":"Susser S","year":"2015","unstructured":"Susser S, Wurzburg J, Ko\ufb02er S, et al. Long-term follow-up analysis of RAVS in HCV NS3, NS5A, and NS5B in DAA therapy failure patients. Abstract P0767. EASL- 50th International Liver Congress; Vienna: 2015"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12837"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i3.327"},{"key":"e_1_3_2_80_1","first-page":"399","article-title":"Low Vitamin D Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection","volume":"29","author":"Gentile I","year":"2015","unstructured":"Gentile I, Scarano F, Celotti A, et al. Low Vitamin D Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection. In vivo 2015;29:399-404","journal-title":"In vivo"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i13.3410"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2015.1059820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:46:41Z","timestamp":1770940001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2015.1059820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,9]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8,3]]}},"alternative-id":["10.1517\/13543784.2015.1059820"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2015.1059820","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}